GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

GATA3 mutations are common in ER-positive breast cancers yet are not targetable. This study describes pharmacological inhibition of MDM2 as a novel approach to target GATA3 deficiency, providing a molecularly guided treatment for this patient subclass associated with a worse prognosis and relapse.

Bibliographic Details
Main Authors: Gaia Bianco, Mairene Coto-Llerena, John Gallon, Venkatesh Kancherla, Stephanie Taha-Mehlitz, Mattia Marinucci, Martina Konantz, Sumana Srivatsa, Hesam Montazeri, Federica Panebianco, Vijaya G. Tirunagaru, Marta De Menna, Viola Paradiso, Caner Ercan, Ahmed Dahmani, Elodie Montaudon, Niko Beerenwinkel, Marianna Kruithof-de Julio, Luigi M. Terracciano, Claudia Lengerke, Rinath M. Jeselsohn, Robert C. Doebele, François-Clément Bidard, Elisabetta Marangoni, Charlotte K. Y. Ng, Salvatore Piscuoglio
Format: Article
Language:English
Published: Nature Portfolio 2022-04-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-022-03296-x

Internet

https://doi.org/10.1038/s42003-022-03296-x

Similar Items